Skip to main content

Table 2 Clinical characteristics of study participants (pSTAT5)

From: Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sjögren’s syndrome

  Healthy Non-severe Severe p-value
n 15 15 16 -
Age (years) 50.3±9.0 59.7±17.2 61.9±17.0 0.66
Sex (% female) 100% 100% 100% NA
Duration from onset (years) - 5.7±10.2a 14.8±10.9a 0.064
Duration from diagnosis (years) - 5.7±7.0 9.8±7.2b 0.079
BMI - 25.6±4.6b 25.3±6.2b 0.88
Stimulated salivary flow rate - 7.2±3.1 ml/5 min 1.5±0.9 ml/5 min 6.66 × 10-9
Schirmer right (mm/5 min) - 8.0±9.3 5.5±5.9b 0.69
Schirmer left (mm/5 min) - 7.9±7.4 6.5±7.0b 0.61
Anti-SSA - 11/73.3% 13/86.7%c 0.39
Anti-SSB - 2/13.3% 5/33.3%c 0.21
Seropositive (SSA and/or SSB) - 11/73.3% 13/86.7%c 0.39
cMARD - 5/35.7%d 4/33.3%e 0.93
bMARD (anti-TNF) - 0/0.0%f 0/0.0%a NA
Glucocorticoid - 3/21.4%d 1/9.1%g 0.44
Cyclosporine eye drops - 3/37.5%h 3/33.3%f 0.91
Oral pilocarpine - 1/14.3%i 1/12.5%h 1
Natural tears - 4/40.0%j 2/28.6%i 0.68
Angina pectoris - 1b 0e 0.38
Autoimmune thyroid disease - 0 2 0.18
Gynaecologic manifestation - 1b 0e 0.38
Anemia - 2b 0e 0.18
Leukopenia - 1b 1e 1
Neutropenia - 1b 0e 0.38
Cancer - 1b 1e 1
  1. Values for continuous variables are presented in mean ± SD. Mann-Whitney U test was used in the comparison between non-severe and severe patients
  2. an=6, bn=13, cn=15, dn=14, en=12, fn=9, gn=11, hn=8, in=7, jn=10